Principal Financial Group Inc. Has $83.83 Million Stock Position in Elevance Health, Inc. $ELV

Principal Financial Group Inc. lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 1.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 259,424 shares of the company’s stock after selling 5,070 shares during the quarter. Principal Financial Group Inc.’s holdings in Elevance Health were worth $83,825,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Activest Wealth Management raised its position in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the period. Vermillion & White Wealth Management Group LLC increased its stake in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the 2nd quarter worth approximately $32,000. Motco lifted its stake in Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. Finally, True Wealth Design LLC boosted its holdings in shares of Elevance Health by 431.8% in the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

Shares of NYSE ELV opened at $342.01 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The business has a 50-day moving average of $351.94 and a 200-day moving average of $329.16. The stock has a market capitalization of $76.01 billion, a price-to-earnings ratio of 13.62, a PEG ratio of 1.93 and a beta of 0.50. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health’s dividend payout ratio is presently 27.23%.

Analyst Ratings Changes

A number of equities research analysts recently commented on ELV shares. Sanford C. Bernstein dropped their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday. UBS Group set a $400.00 target price on Elevance Health in a report on Thursday. JPMorgan Chase & Co. boosted their price target on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday. Robert W. Baird upped their price objective on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, Mizuho set a $413.00 target price on Elevance Health in a research report on Friday, January 9th. Thirteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $396.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.